Review
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Sep 27, 2021; 13(9): 1003-1018
Published online Sep 27, 2021. doi: 10.4254/wjh.v13.i9.1003
Advances in the management of cholangiocarcinoma
Andreas G Zori, Dennis Yang, Peter V Draganov, Roniel Cabrera
Andreas G Zori, Dennis Yang, Peter V Draganov, Roniel Cabrera, Division of Gastroenterology, Hepatology, and Nutrition, University of Florida, Gainesville, FL 32608, United States
Author contributions: Zori AG, Yang D, Draganov PV, and Cabrera R contributed to conception and design of the paper; Draganov PV and Cabrera R revised paper critically for important intellectual content; Zori AG, Yang D wrote majority of the draft;
Conflict-of-interest statement: Zori AG, Draganov PV, and Cabrera R have no conflicts of interest; Yang D is a consultant for Lumendi and Boston Scientific.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Andreas G Zori, MD, Assistant Professor, Division of Gastroenterology, Hepatology, and Nutrition, University of Florida, 1329 SW 16th St Suite 5251, Gainesville, FL 32608, United States. andreas.zori@medicine.ufl.edu
Received: February 26, 2021
Peer-review started: February 26, 2021
First decision: May 3, 2021
Revised: June 9, 2021
Accepted: August 6, 2021
Article in press: August 6, 2021
Published online: September 27, 2021
Core Tip

Core Tip: This review presents recent advances in the management of cholangiocarcinoma with particular focus on the expanding role for liver transplantation, updated guidelines in the use of chemotherapy, novel applications of individualized therapy targeting the specific mutation profile of tumors, and management of malignant biliary obstruction.